Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor

Eye (Lond). 2018 Sep;32(9):1544-1546. doi: 10.1038/s41433-018-0126-z. Epub 2018 May 17.

Authors

Ngoc Chau Isabelle Nguyen¹, Filippo Fabro¹, Aude Ambresin¹, Sakina Ezziat¹, Ciara Bergin¹, Claudia Mazzocato², Irmela Mantel³

Affiliations

¹ Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland.
² Palliative and Supportive Care Service, Department of Medicine, University of Lausanne, Lausanne, Switzerland.
³ Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland. irmela.mantel@fa2.ch.

No abstract available

Publication types

Letter

MeSH terms

Adult
Angiogenesis Inhibitors / administration & dosage*
Bevacizumab / administration & dosage
Eye Pain / etiology*
Humans
Intravitreal Injections / adverse effects*
Ranibizumab / administration & dosage
Receptors, Vascular Endothelial Growth Factor / administration & dosage
Recombinant Fusion Proteins / administration & dosage
Retinal Diseases / drug therapy*
Risk Factors
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
Vascular Endothelial Growth Factor A
aflibercept
Bevacizumab
Receptors, Vascular Endothelial Growth Factor
Ranibizumab